Verastem Inc
VSTM9.540USD
+0.100+1.06%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
586.93MMarket Cap
LossP/E TTM
More Details of Verastem Inc Company
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
Company Info
Ticker SymbolVSTM
Company nameVerastem Inc
IPO dateNov 08, 2011
CEOMr. Daniel W. (Dan) Paterson
Number of employees78
Security typeOrdinary Share
Fiscal year-endNov 08
Address117 Kendrick Street
CityNEEDHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02494
Phone17812924200
Websitehttps://www.verastem.com/
Ticker SymbolVSTM
IPO dateNov 08, 2011
CEOMr. Daniel W. (Dan) Paterson
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
177.64K
-0.74%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.96K
-0.62%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
39.23K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.95K
-11.79%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
16.52K
+101.77%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
Ms. Michelle Robertson
Ms. Michelle Robertson
Independent Director
Independent Director
15.97K
+109.10%
Mr. Matthew E. (Matt) Ros
Mr. Matthew E. (Matt) Ros
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Julissa Viana
Ms. Julissa Viana
Investor Relations
Investor Relations
--
--
Dr. Paul Bunn, M.D.
Dr. Paul Bunn, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
177.64K
-0.74%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.96K
-0.62%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
39.23K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.95K
-11.79%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
16.52K
+101.77%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
6.91%
Balyasny Asset Management LP
6.83%
Logos Global Management LP
5.57%
The Vanguard Group, Inc.
5.56%
Point72 Asset Management, L.P.
5.42%
Other
69.71%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
6.91%
Balyasny Asset Management LP
6.83%
Logos Global Management LP
5.57%
The Vanguard Group, Inc.
5.56%
Point72 Asset Management, L.P.
5.42%
Other
69.71%
Shareholder Types
Shareholders
Proportion
Hedge Fund
34.18%
Investment Advisor/Hedge Fund
20.66%
Investment Advisor
14.73%
Venture Capital
8.37%
Research Firm
6.46%
Private Equity
4.50%
Individual Investor
0.82%
Bank and Trust
0.10%
Pension Fund
0.05%
Other
10.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
222
45.13M
81.89%
-1.03M
2025Q1
244
43.61M
79.40%
-4.23M
2024Q4
235
34.35M
77.18%
-2.65M
2024Q3
242
27.08M
67.33%
+202.45K
2024Q2
244
15.08M
59.39%
-6.47M
2024Q1
256
17.10M
67.53%
-4.40M
2023Q4
273
17.07M
67.53%
-4.59M
2023Q3
291
17.14M
67.93%
-3.81M
2023Q2
301
16.47M
65.35%
+4.17M
2023Q1
312
8.40M
50.30%
-4.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
4.25M
7.73%
+4.25M
--
Mar 31, 2025
Balyasny Asset Management LP
4.79M
8.71%
+842.05K
+21.34%
Mar 31, 2025
The Vanguard Group, Inc.
2.43M
4.42%
+118.60K
+5.13%
Mar 31, 2025
Nantahala Capital Management, LLC
2.30M
4.18%
-1.45M
-38.75%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.33M
4.24%
+51.04K
+2.24%
Mar 31, 2025
State Street Global Advisors (US)
812.15K
1.48%
+70.47K
+9.50%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
ProShares Hedge Replication ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ProShares Hedge Replication ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
Date
Type
Ratio
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
